{
    "nct_id": "NCT03915964",
    "official_title": "A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis",
    "inclusion_criteria": "* Participants must have at least one of the following characteristics:\n\n  * Documented evidence of a VTE prior to this study\n  * At least 60 years of age\n  * A body mass index (BMI) greater than or equal to 30 kilograms per meter squared (kg/m²), or\n  * Age 50 to less than 60 years and BMI 25 to less than 30 kg/m².\n* Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drugs (DMARD) (synthetic or biologic).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participant should have no reason to not take a TNF inhibitor.\n* Participants must not be pregnant or breastfeeding.\n* Participants must not have had more than one VTE.\n* Participants must not have cancer.\n* Participants must not have active herpes zoster, serious infection, active tuberculosis, or any other serious illness.\n* Participants must not have had a live vaccine within four weeks of study start.\n* Participants must not have participated in any other clinical trial within four weeks of study start.\n* Participants must not have a history of IV drug use, other illicit drug abuse, or chronic alcohol abuse in the past year.",
    "miscellaneous_criteria": ""
}